Frontiers in Cancer Science 2024
Matrix, Biopolis
30 Biopolis Street, Singapore 138671
13-15 November 2024 | Singapore
Frontiers in Cancer Science 2024 welcomes you to our 16th International Conference.
We invite scientists, doctors, students and other delegates engaging in scientific research related to cancer to join us at Singapore’s preferred cancer conference.
We bring together distinguished cancer researchers with complementary knowledge and expertise from across the globe for the exchange of ideas and information.
Join us for a time of dynamic interactions and the opportunity to learn from leading cancer experts.
AACR - FCS 2024 Education Session Speakers
Katy REZVANI
Katy REZVANI
MD Anderson Cancer Center, US
Katy Rezvani, MD, PhD is a professor of medicine at the University of Texas MD Anderson Cancer Center, where she serves as the Sally Cooper Murray Chair in Cancer Research, chief of the section for cellular therapy, director of translational research, and medical director of the GMP Facility. She also serves as executive director of MD Anderson's Adoptive Cell Therapy Platform. She leads a research lab with a focus on NK cell biology and developing novel NK cell engineering strategies for cancer, with the aim of translating these discoveries to the clinic. Dr. Rezvani completed her medical training at University College London, England and her PhD at Imperial College London. She completed her training in immunology and transplantation biology at the National Institutes of Health, Bethesda, MD. In addition, she has co-authored over 250 peer-reviewed publications and received multiple prizes and awards, including the American Society of Hematology E. Donnall Thomas award.
Sarah-Maria FENDT
Sarah-Maria FENDT
VIB KU Leuven Center for Cancer Biology, BE
Sarah-Maria Fendt is a Principal Investigator at the VIB Center for Cancer Biology and Professor of Oncology at KU Leuven, Belgium. Sarah has a Master degree of Science in Biochemistry from TU Munich and a PhD in Molecular Systems Biology from the ETH Zurich. Sarah worked as postdoctoral fellow at the Massachusetts Institute of Technology (MIT), before starting her independent research program in 2013. Sarah’s lab is specifically interested in understanding the role of metabolism in driving metastasis formation and in defining the principles of metabolic regulation that enable cancer cells to communicate with and respond to their environment. Her team applies the powerful technologies of single cell and spatial multi-omics analysis in pre-clinical mouse models and patient samples to study this interplay between cancer cells and their metabolic environment. The research of Sarah’s lab has been published in high impact journals including Nature and is currently funded by multiple (inter)national grants and industry, which include an ERC consolidator grant. In 2020 Sarah has been awarded with the highly prestigious EMBO Gold Medal and a Baillet Latour Grant for Medical Research. Moreover, in 2021 Sarah received the Beug Prize for Metastasis Research and she was elected in 2022 as EMBO member.
Zemin ZHANG
Zemin ZHANG
Peking University, CN
Dr. Zemin Zhang is a Professor of Peking University and the Director of BIOPIC (Biomedical Pioneering Innovation Center). He obtained his BS from Nankai University, PhD from Penn State University, postdoctoral trainings at UCSF, and spent >16 years at Genentech/Roche prior to joining Peking University. His lab focuses on understanding the detailed characteristics of the tumor microenvironment, in particular the interplay between immune and cancer cells using adanced genomics technologies, with the goal to identify new therapeutic strategies via modulating the tumor microenvironment. He is a CUSBEA Scholar, a Cheung Kong Scholar, and a member of the Chinese Academy of Sciences.
FCS 2024 International Speakers
Vinod BALACHANDRAN
Vinod BALACHANDRAN
Memorial Sloan Kettering Cancer Center, US
Vinod Balachandran completed his undergraduate degree in Physics at Cornell University, medical degree at the State University of New York at Stony Brook, general surgery residency at Weill Cornell’s New York-Presbyterian Hospital, and complex surgical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSK). In 2015, he joined MSK as faculty, where he is a laboratory head in the Human Oncology and Pathogenesis Program and an attending hepatopancreatobiliary surgeon. His research aims to discover new immunotherapies for pancreatic cancer.
In 2017, Vinod’s group made the striking observation that exceptional survivors of pancreatic cancer have immune-activated tumors infiltrated with T cells that recognize highly immunogenic mutation-derived neoantigens. As pancreatic cancer, and most solid tumors, were presumed to lack clinically relevant neoantigens, this unexpected discovery has spurred efforts to identify, validate, and deliver immunogenic neoantigens to “therapeutically phenocopy” the exceptional survivor state. His group has spearheaded these efforts, including completion of the first clinical trial of personalized mRNA neoantigen vaccines for pancreatic cancer. The positive results of this trial have ignited global interest in mRNA vaccines as next-generation cancer therapies and reinvigorated vaccine oncology.
For his work, Vinod has received a Trailblazer Award for Clinician-Scientists from the Foundation for the NIH, a Damon Runyon Clinical Investigator Award, a Pershing Square Sohn Prize for Young Investigators, and a Louise and Allston Boyer Young Investigator Award for Cancer Research, among others.
Leif BERGSAGEL
Leif BERGSAGEL
Mayo Clinic Arizona, US
Dr. Leif Bergsagel is a Professor of Medicine for the Mayo Clinic College of Medicine, and a consultant in the Division of Hematology and Medical Oncology, Department of Internal Medicine, at Mayo Clinic in Arizona. He is the Principal Investigator of the Mayo Clinic SPORE in Multiple Myeloma, and co-director of the Hematologic Malignancy Program in the Mayo Clinic Cancer Center. He received a B.Sc. degree and M.D. degree from the University of Toronto. He completed an internship in internal medicine and a residency at the University of Toronto Sunnybrook Medical Centre, as well as a residency at Stanford University Medical Center and completed a Fellowship program in Medical Oncology at the National Cancer Institute, Bethesda, MD, where he worked in the laboratory of Dr. Michael Kuehl. After working at Weill Cornell Medical College in New York City, he moved to Mayo Clinic Arizona in 2004. Dr. Bergsagel’s research interest focuses on molecular pathogenesis of multiple myeloma. Working together with his wife, Dr. Marta Chesi, he identified the recurrent chromosome translocations in multiple myeloma, a promiscuous array of mutations that activate the NFKB pathway, and developed a novel transgenic mouse model that faithfully reproduces the genetic, phenotypic, clinical and therapeutic features of human myeloma. An active investigator in many clinical trials, he has led efforts to develop targeted therapy for multiple myeloma, starting with targeting the t(4;14) chromosome translocation that he identified.
Xi CHEN
Xi CHEN
MD Anderson Cancer Center, US
Dr. Xi Chen is an Associate Professor and CPRIT scholar at the Department of Experimental Therapeutics and an Associate Member of the James P. Allison Institute at the University of Texas MD Anderson Cancer Center. Dr. Chen’s laboratory studies how cancer and its immune microenvironment sense and respond to stresses and therapeutic insults to evade immune surveillance and develop drug resistance. They identified the antient Endoplasmic Reticulum stress sensor IRE1a as a critical mediator of therapy resistance in solid tumors, which led to the first-in-human clinical trial of IRE1a RNase inhibitor. They discovered proteostasis network reprogramming as a previously unknown process that mediates therapy resistance to targeted therapies. They also identified ER-Associated Degradation (ERAD) as a protein quality checkpoint that controls hematopoiesis and T cell development.
Sarah-Maria FENDT
Sarah-Maria FENDT
VIB KU Leuven Center for Cancer Biology, BE
Sarah-Maria Fendt is a Principal Investigator at the VIB Center for Cancer Biology and Professor of Oncology at KU Leuven, Belgium. Sarah has a Master degree of Science in Biochemistry from TU Munich and a PhD in Molecular Systems Biology from the ETH Zurich. Sarah worked as postdoctoral fellow at the Massachusetts Institute of Technology (MIT), before starting her independent research program in 2013. Sarah’s lab is specifically interested in understanding the role of metabolism in driving metastasis formation and in defining the principles of metabolic regulation that enable cancer cells to communicate with and respond to their environment. Her team applies the powerful technologies of single cell and spatial multi-omics analysis in pre-clinical mouse models and patient samples to study this interplay between cancer cells and their metabolic environment. The research of Sarah’s lab has been published in high impact journals including Nature and is currently funded by multiple (inter)national grants and industry, which include an ERC consolidator grant. In 2020 Sarah has been awarded with the highly prestigious EMBO Gold Medal and a Baillet Latour Grant for Medical Research. Moreover, in 2021 Sarah received the Beug Prize for Metastasis Research and she was elected in 2022 as EMBO member.
Romina GOLDSZMID
Romina GOLDSZMID
National Cancer Institute, US
Dr. Goldszmid’s research is at the intersection of tumor immunology, myeloid cell biology, and immunity to infections. She received her Ph.D from the University of Buenos Aires, Argentina, part of which was performed as a visiting student in the laboratory of Dr. Ralph Steinman at the Rockefeller University, working on dendritic cell-based vaccines for cancer immunotherapy. She then trained in infectious diseases immunology as a postdoctoral fellow with Dr. Alan Sher at the National Institute of Allergy and Infectious Diseases, NIH. After completing her postdoctoral training, Dr. Goldszmid returned to tumor immunology joining Dr. Giorgio Trinchieri's group as a Staff Scientist at the National Cancer Institute (NCI), where she led pioneering work on the role of the gut microbiota in cancer therapy. In 2015, she was appointed Earl Stadtman Investigator and head of the Inflammatory Cell Dynamics Section in the Laboratory of Integrative Cancer Immunology at NCI. Current work in her laboratory aims to dissect the myeloid cell landscape within tumors, determine their contribution to therapy efficacy, and unravel the mechanisms by which microbiota as well as cues from the tissue’s homeostatic processes regulate their function. Dr. Goldszmid is recipient of the Presidential Early Career Award for Scientists and Engineers (PECASE), NCI Director’s Innovation Award, NCI Director’s Award for Basic Biological Science, NCI CMAP Exceptional Mentor Award, among others.
Douglas R GREEN
Douglas R GREEN
St. Jude Children's Research Hospital, US
Douglas Green, PhD, is the chair of the Immunology Department, co-leader of the Cancer Biology Program and Peter C. Doherty Endowed Chair of Immunology at St. Jude Children’s Research Hospital and has recently elected to the National Academy of Sciences.
Steven JONES
Steven JONES
The University of British Columbia, CA
Dr Jones gained his PhD at the Sanger Institute, Cambridge, where he was involved in the C. elegans genome project. Currently, he is Head of Bioinformatics and Co-Director of the Genome Sciences Centre at BC Cancer in Vancouver. Dr Jones has played a role in numerous other genome projects, including that of the human, mouse, rat, bovine, fruitfly and the SARS coronavirus.
Dr Jones’s research focus is the computational analysis of DNA sequence and the analysis of genomic and transcriptomic data. He has applied next-generation DNA sequencing technology to determine the mutations and rearrangements driving many tumour types. A key goal is to develop bioinformatic approaches to predict the most efficacious therapies from the genetic analysis of patient tumour samples to help guide clinical decision making.
Amongst Dr. Jones many and varied honours and awards he is a Fellow of the Royal Society of Canada as well as the Canadian Academy of Health Sciences. In 2014 and again in 2016, he was named by Thomson Reuters as one of the world's most influential researchers being in the top 1% of cited scientists. In 2018, 2019, and 2020. Dr. Jones is Canada Research Chair in Computational Genomics at the University of British Columbia.
He has been invited to give over 167 presentations, nationally and internationally, is an author on over 535 peer-reviewed publications (Google Scholar h-index 152) and is Principal Investigator and co-applicant on grants that have totaled over $700 million to date.
Rajiv KHANNA
Rajiv KHANNA
QIMR Berghofer Medical Research Institute, AU
Prof. Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR), Brisbane Australia. He is the Co-Director of Queensland Immunology Research Centre and currently appointed as Distinguished Scientist at QIMR Berghofer Medical Research Institute. Prof. Khanna is also appointed as Honorary Professor at the University of Queensland and Griffith University, Brisbane, Australia. Prof. Khanna is a Fellow of Australian Academy of Health and Medical Sciences and was awarded Order of Australia in 2017. He has extensive expertise in immunotherapy clinical trials, herpesvirus immunology and vaccine development. Over the last two decades, his group has successfully translated his research towards the development of novel T cell-based immunotherapeutic strategies for the treatment of transplant recipients and autoimmune diseases. Prof. Khanna is currently appointed as a consultant to Atara Biotherapeutics, Dynavax Technologies and Cellevolve Bio for the development of novel immunotherapeutics, diagnostic technologies and vaccines. He is also appointed on Scientific Advisory Board of Atara Biotherapeutics. Prof. Khanna has been invited by various national and International organizations for expert advice on developing clinical guidelines and scientific review.
David MALKIN
David MALKIN
SickKids, CA
Dr. Malkin is Professor of Pediatrics and Medical Biophysics in the Faculty of Medicine, University of Toronto. He holds the CIBC Children’s Foundation Chair in Child Health Research, is a Staff Oncologist in the Division of Hematology/Oncology, Director of the Cancer Genetics program, and a Senior Scientist in the Genetics and Genome Biology Program at The Hospital for Sick Children in Toronto. Dr. Malkin co-leads the SickKids Precision Child Health initiative. He co-directs the SickKids Cancer Sequencing (KiCS) program which integrates next generation sequencing (NGS) into clinical care of children with cancer, and Director of the pan-Canadian PRecision Oncology For Young peopLE (PROFYLE) initiative which is establishing a pipeline to incorporate NGS into novel clinical trials for children and young adults with hard-to-cure cancers across Canada. Dr. Malkin’s research focuses on genetic mechanisms of childhood cancer susceptibility particularly in the context of TP53 and Li-Fraumeni syndrome. Recently, his work has addressed the application of genomics to clinical surveillance and treatment approaches for children and adults at genetic ‘high risk’ for cancer. Dr. Malkin’s research is funded by a variety of agencies and he has published over 300 peer-reviewed manuscripts. He has received numerous national and international awards recognizing his clinical, research and mentorship work, most recently being elected a Fellow of the Royal Society of Canada in 2022, a Queen’s Platinum Jubilee Community Award in 2023, and elected Fellow of the Academy of the American Association for Cancer Research (AACR) in 2024.
Jeffrey MILLER
Jeffrey MILLER
University of Minnesota, US
Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Dr. Miller is currently a Professor of Medicine at the University of Minnesota. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. He has more than 25 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 300 peer-reviewed publications. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for the Journal of Immunology and Transplantation and Cellular Therapy and is a reviewer for a number of journals and NIH grants. He is an honored double recipient of the National Cancer Institute Outstanding Investigator Award for 2015 and 2023.
Luc MORRIS
Luc MORRIS
Memorial Sloan Kettering Cancer Center, USA
Luc is a physician-scientist who is a surgeon specializing in head and neck oncology at Memorial Sloan Kettering Cancer Center in New York, as well as a US federally-funded laboratory principal investigator. The Laboratory of Experimental Genomics and Immuno-oncology is a multidisciplinary research group that studies the interface between cancer genetics and immune surveillance, by integrating multifaceted genomic and clinical data with mechanistic (molecular genetics, immunology and animal model-based) experimentation, and biostatistical and data science analytic techniques.
Luke O'NEILL
Luke O'NEILL
Trinity College Dublin, IE
Luke O’Neill is Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is a world expert on innate immunity and inflammation. His main research interests include Toll-like receptors, Inflammasomes and Immunometabolism. He is listed by Thompson Reuters/ Clarivates in the top 1% of immunologists in the world, based on citations per paper. Professor O'Neill is co-founder of Sitryx, which aims to develop new medicines for inflammatory diseases. Another company he co-founded, Inflazome was acquired by Roche.
He was awarded the Royal Dublin Society / Irish Times Boyle Medal for scientific excellence, the Royal Irish Academy Gold Medal for Life Sciences, The Society for Leukocyte Biology (SLB) Dolph O. Adams award, the European Federation of Immunology Societies Medal, the Milstein Award of the International Cytokine and Interferon Society and the Landsteiner Award from the Austrian Academy of Sciences. He is a member of the Royal Irish Academy, EMBO (European Molecular Biology Organisation) and a Fellow of the Royal Society.
Katy REZVANI
Katy REZVANI
MD Anderson Cancer Center, US
Katy Rezvani, MD, PhD is a professor of medicine at the University of Texas MD Anderson Cancer Center, where she serves as the Sally Cooper Murray Chair in Cancer Research, chief of the section for cellular therapy, director of translational research, and medical director of the GMP Facility. She also serves as executive director of MD Anderson's Adoptive Cell Therapy Platform. She leads a research lab with a focus on NK cell biology and developing novel NK cell engineering strategies for cancer, with the aim of translating these discoveries to the clinic. Dr. Rezvani completed her medical training at University College London, England and her PhD at Imperial College London. She completed her training in immunology and transplantation biology at the National Institutes of Health, Bethesda, MD. In addition, she has co-authored over 250 peer-reviewed publications and received multiple prizes and awards, including the American Society of Hematology E. Donnall Thomas award.
Zemin ZHANG
Zemin ZHANG
Peking University, CN
Dr. Zemin Zhang is a Professor of Peking University and the Director of BIOPIC (Biomedical Pioneering Innovation Center). He obtained his BS from Nankai University, PhD from Penn State University, postdoctoral trainings at UCSF, and spent >16 years at Genentech/Roche prior to joining Peking University. His lab focuses on understanding the detailed characteristics of the tumor microenvironment, in particular the interplay between immune and cancer cells using adanced genomics technologies, with the goal to identify new therapeutic strategies via modulating the tumor microenvironment. He is a CUSBEA Scholar, a Cheung Kong Scholar, and a member of the Chinese Academy of Sciences.
FCS 2024 Local Speakers
Jinmiao CHEN
Jinmiao CHEN
Duke-NUS Medical School
Jinmiao Chen obtained her bachelor’s degree in computer science from Sun Yat-sen University, China in 2002, before completing a PhD degree in machine learning and artificial intelligence at Nanyang Technological University, Singapore in 2007. Chen then joined the bioinformatics core of the A*STAR Singapore Immunology Network as a postdoctoral research fellow, where she analyzed microarrays, next generation sequencing, microbiome/metagenomics, high dimensional flow/mass cytometry and single-cell RNA-sequencing data. In 2014, she established her own research lab at SIgN as a Project Leader;. she is now a Principal Investigator at SIgN focusing on single-cell computational/system immunology. Chen is currently an Associate Professor at Duke-NUS Medical School Singapore.
Melvin CHUA
Melvin CHUA
National Cancer Centre Singapore
Dr Chua is a Clinician-Scientist at the NCCS and Duke-NUS Medical School, and Principal Investigator of the Precision Radiotherapeutics and Oncology Programme, Division of Medical Sciences, supported by the NMRC Clinician-Scientist Award. He is also the Head of Department and Senior Consultant for Head and Neck and Thoracic Cancers, Division of Radiation Oncology, and Director of the Data and Computational Science Hub at the NCCS. He has obtained more than 70 million dollars in research funding, and his research focuses on the development of Phase II-III clinical trials in nasopharyngeal (NPC) and prostate cancers. He also runs a laboratory that is involved in data science and omics analytics that help with therapeutic and biomarker discovery for these cancer types. He is jointly appointed as an Associate Professor (On Tenure) with the Duke-NUS Medical School, Singapore; and is a Visiting Professor of Zhongnan Hospital of Wuhan University, China. Dr Chua is also the Chair of the ASCO Asia Pacific Regional Council, and Program Committee Chair of the ASCO Breakthrough Meeting 2024. Dr Chua received numerous honours such as SingHealth Excellence Distinguished Researcher Award (2021), Conquer Cancer Foundation ASCO Merit Award (2013, 2015, 2016), NMRC Clinician-Scientist Award (Investigator, 2017, 2021), Fellow of the Royal College of Radiologists (2013), and Fellow of the Academy of Medicine Singapore (FAMS, 2021).
Marco FOIANI
Marco FOIANI
Cancer Science Institute of Singapore
A molecular biologist by training, Marco Foiani is professor at the National University of Singapore (NUS) and senior principal investigator at the Cancer Science Institute (CSI) of Singapore. Foiani obtained his Ph.D in molecular and cell biology from University of Milan in 1988. in 1989, he moved to the National Institute of Health (NICHD) in Bethesda, USA for his post-doctoral studies and remained there till 1991. In 1991, he joined as an assistant professor the University of Milan where he started his career in the field of chromatin dynamics. He became associate professor (1995) and subsequently professor (2001) at the University of Milan. He was one of the first scientists to join IFOM. The Genome integrity research lab started functioning in 2000 with the aim of studying the various pathways that safeguard genomic integrity and play a role in oncogenesis. He was he Scientific Director of IFOM (2009 to 2022). He has been a member of the editorial board of Cell (2009-2019), and is a member of the Academia Europea and EMBO. His major contributions are within the fields of chromosome dynamics and genome integrity. His work has contributed to elucidate the ATR and ATM-dependent checkpoint processes controlling the interfaces between DNA replication, recombination, transcription and DNA topology and preventing abnormal chromosome transitions. In recent years, focus of his research has geared more towards the connections between cell metabolism and genome integrity pathways and between chromosome dynamics and mechano-transduction circuits controlling cell and nuclear plasticity.
Vaidehi KRISHNAN
Vaidehi KRISHNAN
Duke-NUS Medical School
Vaidehi Krishnan is a Principal Research Scientist at the Cancer & Stem Cell Biology Programme at the Duke-NUS Medical School in Singapore. Vaidehi obtained her PhD in Biochemistry from Tata Memorial Hospital, India. Subsequently, her research has focused on understanding how genomic integrity is disrupted in aging and cancer. Over the last few years, her work has involved the use of single-cell approaches to uncover novel features of drug resistance in Chronic Myeloid Leukemia (CML). The aim of the work is to develop biomarkers of drug resistance and discover novel immunotherapeutic approaches to improve patient outcomes in CML.
Jonathan Wei Jie LEE
Jonathan Wei Jie LEE
National University Hospital
Dr Jonathan Lee is a consultant specializing in Gastroenterology and Hepatology at National University Hospital, Singapore, as well as an Assistant Professor at NUS Yong Loo Lin School of Medicine. He currently services as the director of Research, for the division of Gastroenterology and Hepatology. Dr Lee completed a two-year full-time overseas NRMC research training fellowship (2019-2021) at the Broad Institute, USA, under Prof Ramnik Xavier, focusing on microbiome multi-omics. Dr Jonathan Lee has a keen interest in translational microbiome medicine and drives the fecal microbiota transplant clinical service at the National University Hospital, Singapore. His research interest is in studying the role of microbiome associated with gastrointestinal diseases, whereby he previously used microbial metagenomics to prognosticate patients with inflammatory bowel disease and colorectal adenomatous polyps. He is currently a principal investigator for multiple ongoing basic and translational research in this field.
Yinghui LI
Yinghui LI
Nanyang Technological University
Dr Yinghui Li is a Nanyang Assistant Professor in the School of Biological Sciences (NTU) and an adjunct Principal Investigator in the Institute of Molecular and Cell Biology (A*STAR). She obtained her Bachelor’s degree in Life Sciences at the National University of Singapore and completed her doctoral research at Karolinska Institutet in the laboratory of Professor Sven Pettersson, where she investigated the role of inflammation and host-gut microbiota interactions in intestinal tumorigenesis. She then conducted her postdoctoral training in Professor Vinay Tergaonkar’s laboratory at the Institute of Molecular and Cell Biology (IMCB), where she characterized the mechanisms of telomerase reactivation at mutant TERT promoters in human glioblastoma and melanoma. She was awarded the Nanyang Assistant Professorship and National Research Foundation (NRF) fellowship in 2018 when she joined NTU. Her lab’s research is currently focused on understanding how the chromatin is dysregulated during cancer progression and the impact of aberrant oncogenic pathways such as NF-κB signalling in the cancer epigenome.
Wai Leong TAM
Wai Leong TAM
Genome Institute of Singapore, A*STAR, Singapore, Cancer Science Institute of Singapore
Wai Leong TAM performed his PhD research on stem cell biology at the Genome Institute of Singapore (GIS, A*STAR). He undertook his postdoctoral training at the Whitehead Institute/MIT, where he concentrated on understanding breast cancer stem cell biology and cancer metastasis. He then joined the GIS and the Cancer Science Institute of Singapore as a faculty member. His lab focuses on uncovering emerging paradigms of cancer stem cells, specifically in the areas of cancer metabolism, cell state transitions, and tumor microenvironment. Current efforts are focused on identifying and validating preclinical targets that can lead into drug development, as well as translating fundamental discoveries into paradigms that can help change and advance clinical practice.
Andrew Nguan Soon TAN
Andrew Nguan Soon TAN
Nanyang Technological University
Associate Professor Andrew Tan serves as the Vice-Dean (Faculty Affairs) at LKCMedicine and holds a joint appointment at the School of Biological Sciences, Nanyang Technological University. He completed his Ph.D. at the National University of Singapore before advancing to a postdoctoral fellowship at the Center for Integrative Genomics in Switzerland. There, he explored the peroxisome proliferator-activated receptor in skin wound repair and metabolic syndrome, leading to the discovery of angiopoietin-like 4 (Angptl4) as a direct target of PPAR. This protein plays a critical role as a redox modulator and matricellular protein, linking inflammation to increased risks of metastasis and metabolic disorders. Upon returning to Singapore, Prof. Tan has centered his research on the complex roles of Angptl4 in disease progression, particularly its impact on metastasis and wound healing. His pioneering work has advanced our understanding of oxidative stress-driven metastasis and the intercellular communications that influence vascular permeability. Currently, he is dedicated to applying precision nutrition strategies to enhance gut health and manage hepatic oxidative stress, particularly in patients with metabolic dysfunction-associated steatotic liver disease.
Xiaoyu SONG
Xiaoyu SONG
Duke-NUS Medical School
Dr. Xiaoyu Song’s primary research interest is the development of statistical methods for omics data analysis. The omics data include genomics, epigenomics, transcriptomics, proteomics, and phenotypes, collected at the subject, tissue, or single-cell levels, with and without spatial features. Dr. Song has developed a suite of tools for their association, prediction, integration, visualization, and network analysis, shedding light on the molecular and cellular mechanisms of cancer and other complex human diseases. Dr. Song’s research has been funded by >10 National Institute of Health (NIH) grants in the US, and generated >50 manuscripts in esteemed statistical and biological journals, such as Journal of the American Statistical Association (JASA) and Cell.
David VIRSHUP
David VIRSHUP
Duke-NUS Medical School
David Virshup, M.D., is Director of the Programme in Cancer and Stem Cell Biology (CSCB) and Professor at Duke-NUS Medical School and is jointly appointed as Professor of Pediatrics at Duke University in North Carolina.
Dr. Virshup received his B.A. magna cum laude from Beloit College, majoring in chemistry. He received his M.D. from Johns Hopkins University in Baltimore, followed by clinical residency in Pediatrics and a fellowship in Pediatric Hematology/Oncology. He credits his research training and mentoring to William Zinkham, Vann Bennett, and Tom Kelly in the departments of Pediatrics, Cell Biology and Anatomy, and Molecular Biology and Genetics, all at Hopkins. Dr. Virshup established his first independent laboratory at the University of Utah in Salt Lake City, where over the course of 17 years he rose to Professor of Pediatrics and Oncological Sciences with an endowed chair as an investigator at the Huntsman Cancer Institute. He moved to Duke-NUS in Singapore in 2007 to help establish CSCB.
He has been elected to several honorific societies including the American Society for Clinical Investigation (ASCI), the American Association for the Advancement of Science (AAAS) and the Association of American Physicians (AAP). He is board certified in both Pediatrics and Pediatric Hematology/Oncology in the USA.
His research has focused on signal transduction, with an emphasis on both Wnt signaling and circadian rhythms. Early work examined the roles of Protein Phosphatase 2A and Casein Kinase 1 play in these processes. In Singapore, studies of phosphorylation of the PERIOD protein lead to the elucidation of the phosphoswitch model controlling circadian clock speed. In addition, his laboratory collaborated to develop a small molecule inhibitor of Wnt secretion, ETC-159, a drug now in human clinical trials.
Valerie Shiwen YANG
Valerie Shiwen YANG
National Cancer Centre Singapore, Institute of Molecular and Cell Biology, A*STAR
Assistant Professor Valerie Yang is a Clinician-Scientist. She is Consultant, Division of Medical Oncology at the National Cancer Centre Singapore. She is jointly appointed as Research Clinician & Group Leader at the Institute of Molecular and Cell Biology, A*STAR, where she leads the Translational Precision Oncology Laboratory. Her interests includes rare and young people cancers such as sarcomas, skin cancers and Asian melanomas, as well as lymphomas. She is a National Science Scholar, graduand of the MB/PhD program at the University of Cambridge, and winner of multiple national and international grant awards.
Timeline
Venue
Matrix, Biopolis
30 Biopolis Street, Singapore 138671
Nearest MRT station: Buona Vista MRT Station (Exit D), walk for 7 mins (500m) to reach the venue.
Bus Services: 14, 74, 91, 92, 92A, 95, 95B, 191, 196, 198, 200, 200A
Click on the Google Maps link below to check directions from your starting point.
Registration
- Please note that entry to the conference is strictly by registration only.
- Please note that entry to a single talk on a complimentary basis is STRICTLY not allowed.
- Registrations will allow admission to all scientific sessions, poster sessions, exhibition booths and lunch receptions.
- For group registrations, please contact the conference secretariat.
- Conference badges can be collected at the reception counter at the commencement of the conference.
- All registered participants are requested to display the conference badge visibly at all times during the conference for identification.
- Registration passes are strictly not transferable.
- Unutilized registrations are strictly non-refundable.
- For group registrations, if a registered delegate has left the organization, the registration MUST BE cancelled; replacements are not allowed. The cancellation and refund policy applies.
- For group registrations (affiliates), please register latest by 6 November 2024, 23 59 SGT. Afterwhich, payment has to be made upfront upon registration.
- For all registrations, cancellations must be made latest by 23 October 2024, 23 59 SGT. Cancellations are strictly not allowed after the above date.
- Payments are debited to ‘National University of Singapore’.
- Payments must be made online via a credit card at the point of online registration.
- All Registration Fees are subject to prevailing GST
- FCS accepts the following credit cards:
-
- American Express
- MasterCard
- Visa
- After completing the registration form, you will be prompted to make payment online via a credit card.
- In the event your payment fails, please kindly arrange for payment via another credit card.
- After completing the online payment, you will receive an acknowledgment for your registration and payment. However, please note that registrations are not confirmed until funds are received.
- Please allow 7 working days for the updating of your payment in our records.
- Once payments have been received, a confirmation email will be sent to you informing that your registrations are confirmed.
- For your records, please print a copy of the confirmation email.
- For group registrations, an invoice will be sent after registration closes.
- For other payment methods, please contact the conference secretariat.
Abstract Submission
◊ The 'Outstanding FCS Abstract Travel Award' will be given out to selected abstracts to cover their expenses to present their oral abstract in-person at #FCS2024!
◊ Top poster abstracts stand a chance to win AACR travel awards to facilitate their attendance at AACR 2025!
Oral Presentation and Poster Presentation
- Abstracts are limited to a total maximum of 300 words, excluding authors’ affiliations.
- All abstract titles should be in Title Caps.
- Please submit your abstracts as an attachment in MS Word Format.
- Authors’ affiliations should be submitted in the following sample format:
Peter Tan1,21Cancer Science Institute of Singapore, 2Department of Medicine, National University of Singapore - Please avoid adding graphics, charts or photographs in your abstracts; they should only be included in your poster.
- Please ensure that all special characters / symbols and formatting are properly displayed in your submission.
- Please refer to the Abstract Template provided.
- Please note that selected abstracts may be included in the E-program/abstract booklet that participants will receive upon registration.
- Deadline for Submission for Oral and Poster Presentation: 11 August 2024
- Please indicate your interest in either the oral and/or poster presentation categories which you are submitting for. Successful Oral Presenters will be able to present their work during the Frontiers in Cancer Science 2024’s programme.
- Results for Oral Presentation abstracts will be announced at least 3 weeks before the conference.
- Abstract submissions are free.
- All abstracts submitted must represent scientific research relevant to the studies of cancer research.
- Authors submitting abstracts are responsible for ensuring that all authors listed on the abstract have been notified of the submission.
- Abstracts must be submitted by the presenting author.
- Preliminary Selection: All abstracts received will be assessed by members of the Review Committee, who are authorized to decide if an abstract shall be accepted to participate in the FCS 2024 Posters Presentation and/or Oral Presentation.
- Only submitters of accepted abstracts will be notified about the acceptance via email.
- All accepted posters, poster presentations and oral presentations will be reviewed by the appointed panel of Poster Judges.
- Please ensure that the abstracts you have submitted are accurate; no revisions can be made after the abstract has been submitted.
- Submission of your abstract/s implies that you have read, understood and comply with the Terms and Conditions as outlined.
- Results of the poster presentations and oral presentations will be announced on Thursday, 14 November 2024 and awards will be presented to the winners on Friday, 15 November 2024.
Abstract submission is a simple two-step process.
Step 1: Prepare your abstract using the Abstract Template provided.
Please download the Abstract Template here.
Step 2: Complete and submit an Abstract Submission Form.
Please fill in your Abstract Submission Form.
Abstract Submitter Registration
- The invitation to submit an abstract does not constitute an offer to pay travel, accommodation or registration costs associated with the Conference.
- Submitters of accepted abstracts will receive registration waivers.
- By submitting an abstract, submitters are responsible for gaining appropriate permissions from the copyright holder.
- Successful Poster abstract submitters will be notified via email by mid September 2024*.
- Successful Oral abstract submitters will be notified via email by mid September 2024*.
- Participants of the FCS Posters Presentations should print a physical poster that is A1-sized, colored and of portrait orientation and bring it along to be displayed at the conference.
- Results will be announced on Thursday, 14 November 2024.
- Certificates of award and prizes will be presented to the winners at the end of the conference on Friday, 15 November 2024.
* Dates are subject to change, please check back for updates.
Past Conferences
FCS 2023
FCS 2023
NUS University Cultural Centre
Shelley BERGER (virtual), University of Pennsylvania, USA
Tom James CARNEY, Lee Kong Chian School of Medicine, Singapore
Polly Leilei CHEN, Cancer Science Institute of Singapore
Sanjay DE MEL, National University Cancer Institute Singapore
Scott DIXON, Stanford University, USA
Christian HACKENBERGER, FMP Berlin, DE
Mien-Chie HUNG, China Medical University, TW
Anand JEYASEKHARAN, Cancer Science Institute of Singapore & National University Cancer Institute Singapore
Calvin KUO, Stanford University, USA
Thi Nguyet Minh LE, National University of Singapore
Jianjun LIU, Genome Institute of Singapore
Stephanie MA, The University of Hong Kong, HK
Babita MADAN, Duke-NUS Medical School, Singapore
Manolis PASPARAKIS, University of Cologne, DE
Shazib PERVAIZ, National University of Singapore
Bin Tean TEH, National Cancer Centre Singapore
Michel TREMBLAY, McGill University, CA
Karen VOUSDEN, The Francis Crick Institute, UK
Mei WANG-CASEY, Duke-NUS Medical School, Singapore
Valerie Shiwen YANG, Institute of Molecular and Cell Biology, Singapore
Timothy YAP, MD Anderson Cancer Center, US
Lee ZOU, Duke University School of Medicine, US
FCS 2022
FCS 2022
Lee Kong Chian School of Medicine (Novena Campus)
Antonio BERTOLETTI, Duke-NUS Medical School, Singapore
Shruti BHATT, National University of Singapore
Christina CURTIS, Stanford University, USA
David M. EPSTEIN, Black Diamond Therapeutics, USA
Ernesto GUCCIONE, Icahn School of Medicine at Mount Sinai, USA
Jiaoti HUANG, Duke University School of Medicine, USA
Gopal IYER, National Cancer Centre Singapore
Jingmei LI, Genome Institute of Singapore
Soon Thye LIM, National Cancer Centre Singapore
Paul S. MISCHEL, Stanford University, USA
Sin Tiong ONG, Duke-NUS Medical School, Singapore
Kristijan RAMADAN, University of Oxford, UK
Victoria SEEWALDT, City of Hope National Medical Center, USA
Ramesh A. SHIVDASANI, Dana-Farber Cancer Institute, USA
John SILKE, The Walter and Eliza Hall Institute, Australia
Toshio SUDA, Cancer Science Institute of Singapore
Joseph SUNG, Lee Kong Chian School of Medicine, Singapore
Ian Bee Huat TAN, National Cancer Centre Singapore
Patrick TAN, Genome Institute of Singapore
Yvonne TAY, Cancer Science Institute of Singapore
Matthew VANDER HEIDEN, Massachusetts Institute of Technology, USA
Roel VERHAAK, The Jackson Laboratory, USA
Carmen Chak-Lui WONG, The University of Hong Kong, Hong Kong
Sunny WONG, Lee Kong Chian School of Medicine, Singapore
Joe YEONG, Institute of Molecular and Cell Biology, Singapore
FCS 2021
FCS 2021
ZOOM
Timothy CHAN, Cleveland Clinic, USA
Gerard EVAN, University of Cambridge, UK
Bernard FOX, Earle A. Chiles Research Institute, Providence Cancer Institute
Mathew GARNETT, Wellcome Sanger Institute, UK
Thomas F. GAJEWSKI, University of Chicago, USA
Jesús GIL VALLES, Imperial College London, UK
Chuan HE, University of Chicago, USA
Jerry SHAY, UT Southwestern Medical Center, USA
Charles SWANTON, Francis Crick Institute, UK
Clotilde THÉRY, Institut Curie, France
Glenn Kunnath BONNEY, National University of Singapore
Xiaoyuan CHEN, National University of Singapore
Melissa Jane FULLWOOD, School of Biological Sciences, NTU & Cancer Science Institute of Singapore
Jonathan GÖKE, Genome Institute of Singapore, A*STAR, Singapore
Chin-Ann Johnny ONG, National Cancer Centre Singapore
David SP TAN, National University Cancer Institute, Singapore
Carol TANG, National Neuroscience Institute
TEH Bin Tean, Institute of Molecular and Cell Biology, A*STAR, Singapore
Lisa TUCKER-KELLOGG, Duke-NUS Medical School
Qi ZENG, Institute of Molecular and Cell Biology, A*STAR, Singapore
Franklin ZHONG, Lee Kong Chian School of Medicine
FCS 2020
FCS 2020
ZOOM
Susan CLARK, Garvan Institute of Medical Research, Australia
Ronald DePINHO, MD Anderson Cancer Center, USA
Rani E GEORGE, Dana Farber Medical School, USA
Marco HEROLD, Walter and Eliza Hall Institute of Medical Research, Australia
Ricky JOHNSON, Peter MacCallum Cancer Centre, Australia
Kenneth KINZLER, Ludwig Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, USA
Muthiah MANOHARAN, Alynlam Pharmaceuticals, USA
Antoni RIBAS, University of California, Los Angeles, USA
Ali SHILATIFARD, Northwestern University, USA
Erwei SONG, Sun-Yat-Sen Memorial Hospital, China
Melvin CHUA, National Cancer Centre, Singapore
Ray DUNN, Lee Kong Chian School of Medicine, Singapore
Boon Cher GOH, National University Cancer Institute of Singapore
Takaomi SANDA, Cancer Science Institute of Singapore
Anders SKANDERUP, Genome Institute of Singapore, A*STAR, Singapore
Raghav SUNDAR, National University Cancer Institute of Singapore
Puay Hoon TAN, Singapore General Hospital
Yee Joo TAN, Institute of Molecular and Cell Biology, A*STAR, Singapore
FCS 2019
FCS 2019
Academia @ SGH
Sir Gregory WINTER, University of Cambridge, UK
Sung Hee BAEK, Seoul National University, South Korea
Yinon BEN-NERIAH, Hebrew University-Hadassah Medical School, Israel
Maria FIGUEROA, University of Miami, USA
Sankar GHOSH, Columbia University, USA
Margaret A. GOODELL, Baylor College of Medicine, USA
Michael N. HALL, Biozentrum University of Basel, Switzerland
Lijian HUI, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, China
David KOMANDER, Walter and Eliza Hall Institute of Medical Research, Australia
Ira MELLMAN, Genetech, USA
Dorothy A. SIPKINS, Duke Univesity, USA
Nahum SONENBERG, McGill University, Canada
Sabine TEJPAR, Katholieke Universiteit Leuven, Belgium
Jing YANG, University of California, San Diego, USA
Yi Arial ZENG, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, China
Bing ZHU, Institute of Biophysics, Chinese Academy of Sciences, China
Jason CHAN, National Cancer Centre, Singapore
Polly Leilei CHEN, Cancer Science Institute of Singapore
Valerie CHEW, Singhealth, Singapore
Edward Kai-Hua CHOW, Cancer Science Institute of Singapore
Ramanuj DASGUPTA, Genome Institute of Singapore, A*STAR, Singapore
Nai Yang FU, Duke-NUS Medical School, Singapore
Jonathan GÖKE, Genome Institute of Singapore, A*STAR, Singapore
HONG Wanjin, Institute of Molecular and Cell Biology, A*STAR, Singapore
William HWANG, National Cancer Centre Singapore
Philipp KALDIS, Institute of Molecular and Cell Biology, A*STAR, Singapore
Joanne NGEOW, Lee Kong Chian School of Medicine, Singapore
Derrick ONG Sek Tong, National University of Singapore
Jason J. PITT, Cancer Science Institute of Singapore
Steven G. ROZEN, Duke-NUS Medical School, Singapore
Daniel Shao-Weng TAN, National Cancer Centre Singapore
Wee-Wei TEE, Institute of Molecular and Cell Biology, A*STAR, Singapore
FCS 2018
FCS 2018
University Cultural Centre, NUS
Omar ABDEL – WAHAB, Memorial Sloan Kettering Cancer Centre, USA
Stephen BAYLIN, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
Karlene CIMPRICH, Stanford University, USA
James DECAPRIO, Harvard Medical School, USA
Vishva DIXIT, Genetech, USA
Andrew FIRE, Stanford University School of Medicine, USA
Elaine FUCHS, Howard Hughes Medical Institute and the Rockefeller University, USA
Geoff LINDEMAN, Eliza Hall Institute of Medical Research, Australia
Hiroshi MAEDA, Kumamoto University, Japan
Paul MODRICH, Duke University, USA
Anjana RAO, University of California San Diego, USA
Feyruz RASSOOL, University of Maryland, USA
Andrew ROBERTS, Eliza Hall Institute of Medical Research, Australia
Serrano MANUEL, Barcelona Institute of Science and Technology, Spain
Tony TIGANIS, Monash University, Australia
Fred BARD, Institute of Molecular and Cell Biology, Singapore
Ernesto GUCCIONE, Institute of Molecular and Cell Biology, Singapore
N Gopalakrishna IYER, National Cancer Centre, Singapore
Sudhakar JHA, Cancer Science Institute of Singapore
H Phillip KOEFFLER, National University Cancer Institute, Singapore
LI Shang, Duke-NUS Medical School, Singapore
Prabha SAMPATH, Institute of Medical Biology, A*STAR, Singapore
TAM Wai Leong, Genome Institute of Singapore, A*STAR, Singapore
Patrick TAN, Duke-NUS Medical School, Singapore
Daniel TENEN, Cancer Science Institute of Singapore
Vinay TERGAONKAR, Institute of Molecular and Cell Biology, Singapore
Navin Kumar VERMA, Lee Kong Chian School of Medicine, Singapore
Virgile VIASNOFF, Mechanobiology Institute, National University of Singapore
David VIRSHUP, Duke-NUS Medical School, Singapore
Mei WANG, Duke-NUS Medical School, Singapore
Hanry YU, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
YU Qiang, Genome Institute of Singapore, A*STAR, Singapore
FCS 2017
FCS 2017
Matrix Auditorium, Biopolis
Shizuo AKIRA, Osaka University, Japan
CHEN Ye-Guang,Tsinghua University, China
Mark DAWSON, Peter MacCallum Cancer Centre, Australia
Gen-Sheng FENG, University of California, San Diego, USA
Xi HE, Boston Children’s Hospital, USA
Michael T HEMANN, Massachusetts Institute of Technology, USA
Raghu KALLURI, MD Anderson Cancer Center, USA
Rong LI, Johns Hopkins, USA
Roeland NUSSE, Stanford University, USA
Ann Marie PENDERGAST, Duke University, USA
Danny REINBERG, NYU & Howard Hughes Medical Institute, USA
Laura SOUCEK, Vall d’Hebron Institute of Oncology (VHIO), Spain
Ulrich STEIDL, Albert Einstein College of Medicine, USA
Stephen C. WEST, London Research Institute, UK
Jeff WRANA,University of Toronto, Canada
Jean ZHAO, Dana-Farber Cancer Institute, USA
CHNG Wee Joo, National University Cancer Institute, Singapore
Hyungwon CHOI , Institute of Molecular and Cell Biology, Singapore
David EPSTEIN , Duke-NUS Medical School, Singapore
Koji ITAHANA, Duke-NUS Medical School, Singapore
Anand JEYASEKHARAN, National University Cancer Institute, Singapore
Dennis KAPPEI, Cancer Science Institute of Singapore
David LANE, A*STAR, Singapore
Jonathan LOH, Institute of Molecular and Cell Biology, Singapore
ONG Choon Kiat, National Cancer Centre Singapore
Shyam PRABHAKAR, Genome Institute of Singapore
Giulia RANCATI, Institute of Medical Biology, Singapore
Kanaga SABAPATHY, National Cancer Centre Singapore
Yvonne TAY, Cancer Science Institute of Singapore
TOH Han Chong, National Cancer Centre Singapore
WANG Xiaomeng, Lee Kong Chian School of Medicine, Singapore
ZHAI Weiwei, Genome Institute of Singapore
FCS 2016
FCS 2016
University Cultural Centre, NUS
William KAELIN (KEYNOTE), Dana Farber Cancer Institute, USA
Michael KARIN (KEYNOTE), University of California San Diego, USA
Cheryl H. ARROWSMITH, University of Toronto, Canada
Kimberly L. BLACKWELL, Duke University, USA
Navdeep S. CHANDEL, Northwestern University, USA
Robert EISENMAN, Fred Hutchinson Cancer Research Center, USA
Tak Wah MAK, University of Toronto, Canada
Jean-Christophe MARINE, VIB-KU Leuven, Belgium
Bing REN, University of California, San Diego, USA
Shimon SAKAGUCHI, Osaka University, Japan
Michael TAYLOR, The Hospital for Sick Children (SickKids), Canada
Hong WU, Peking University, China
Michael B. YAFFE, Massachusetts Institute of Technology, USA
Antonio BERTOLETTI, Duke-NUS Medical School, Singapore
Edward Kai-Hua CHOW, Cancer Science Institute of Singapore
Pierce Kah Hoe CHOW, National Cancer Centre Singapore
Balram CHOWBAY, National Cancer Centre Singapore
Karen CRASTA, Lee Kong Chian School of Medicine
Melissa J. FULLWOOD, Cancer Science Institute of Singapore
HONG Wanjin, Institute of Molecular and Cell Biology, Singapore
Philipp KALDIS, Institute of Molecular and Cell Biology, Singapore
LEE Sang Hyun, Duke-NUS Medical School, Singapore
LEE Soo Chin, National University Cancer Institute, Singapore
ONG Sin Tiong, Duke-NUS Medical School
Andrea PAVESI, SMART, Singapore
Takaomi SANDA, Cancer Science Institute of Singapore
Iain TAN Bee Huat, National Cancer Centre Singapore
Reshma TANEJA, National University of Singapore
WOO Wei Meng, Lee Kong Chian School of Medicine, Singapore
FCS 2015
FCS 2015
University Cultural Centre, NUS
Ashok R. VENKITARAMAN (KEYNOTE), University of Cambridge, UK
Tony HUNTER (KEYNOTE), Salk Institute of Biological Studies, USA
Bruno AMATI, Italian Institute of Technology (IIT), Italy
Axel BEHRENS, The Francis Crick Institute, UK
Christopher M. COUNTER, Duke University Medical Center, USA
Amato J. GIACCIA, Stanford University School of Medicine, USA
Laurie H. GLIMCHER, Weill Cornell Medical College, USA
Florian R. GRETEN, Georg Speyer Haus, Germany
Michael C. JENSEN, University of Washington, USA
Randall S. JOHNSON, University of Cambridge, UK
Jan KARLSEDER, Salk Institute for Biological Studies, USA
Gerry MELINO, MRC Toxicology Unit, University of Leicester, UK
Raul MOSTOSLAVSKY, MGH Cancer Center, Harvard Medical School, USA
Andreas STRASSER, The Walter and Eliza Hall Institute, Australia
Nathalie WONG, The Chinese University of Hong Kong
Masayuki YAMAMOTO, Tohoku University, Japan
Frederic BARD, Institute of Molecular and Cell Biology, Singapore
Ramanuj DASGUPTA, Genome Institute of Singapore
Ernesto GUCCIONE, Institute of Molecular and Cell Biology, Singapore
HUI Kam Man, National Cancer Center Singapore
Philip W. INGHAM, Lee Kong Chian School of Medicine, Singapore
Sudhakar JHA, Cancer Science Institute of Singapore
Par L. NORDLUND, Nanyang Technological University, Singapore
Motomi OSATO, Cancer Science Institute of Singapore
SHEN Han-Ming, National University of Singapore
David SP TAN, National University Cancer Institute, Singapore
Daniel G. TENEN, Cancer Sciencce Institute of Singapore
Vinay TERGAONKAR, Institute of Molecular and Cell Biology, Singapore
David M. VIRSHUP, Duke-NUS Graduate Medical School, Singapore
Mei WANG, Duke-NUS Graduate Medical School, Singapore
FCS 2014
FCS 2014
The Academia, Singapore
Michael B. KASTAN (KEYNOTE), Duke University, USA
Geneviève ALMOUZNI, Institut Curie, France
Steven ARTANDI, Stanford University, USA
FENG Cong, Novartis Institutes for Biomedical Research, USA
Brian HUNTLY, University of Cambridge, UK
Charles G. MULLIGHAN, St Jude Children’s Research Hospital, USA
Seishi OGAWA, Kyoto University, Japan
Emmanuelle PASSEGUÉ, University of California, San Francisco, USA
Duanqing PEI, Guangzhou Institutes of Biomedicine and Health (GIBH), China
Eric SO, King’s College London
Terry SPEED, The Walter and Eliza Hall Institute of Medical Research, Australia
Nicholas K. TONKS, Cold Spring Harbor Laboratory, USA
Marian L. WATERMAN, University of California, Irvine, USA
Nicholas BARKER, Institute of Medical Biology, Singapore
Curtis A. DAVEY, Nanyang Technological University, Singapore
Pieter EICHHORN, Cancer Science Institute of Singapore
Mikael HARTMAN, National University Cancer Institute, Singapore
Yoshiaki ITO, Cancer Science Institute of Singapore
Philipp KALDIS, Institute of Molecular and Cell Biology, Singapore
Koji KONO, Cancer Science Institute of Singapore
Caroline LEE, National Cancer Centre Singapore
Shang LI, Duke-NUS Graduate Medical School, Singapore
Paul A. MACARY, National University of Singapore
Sven PETTERSSON, National Cancer Centre Singapore
David L. SILVER, Duke-NUS Graduate Medical School, Singapore
Jean-Paul THIERY, National University of Singapore
David William TOWNSEND, A*STAR-NUS Clinical Imaging Research Centre, Singapore
FCS 2013
FCS 2013
Matrix, Biopolis
Alan ASHWORTH (KEYNOTE), The Institute of Cancer Research, UK
Iannis AIFANTIS, NYU Cancer Institute, USA
Rene BERNARDS, The Netherlands Cancer Institute, The Netherlands
Kun-Liang GUAN, University of California, San Diego
Carl-Henrik HELDIN, Ludwig Institute for Cancer Research Uppsala, Sweden
Guillermina (Gigi) LOZANO, MD Anderson Cancer Center, USA
Nickolas PAPADOPOULOS, The Johns Hopkins University, USA
Luis PARADA, The University of Texas Southwestern Medical Center, USA
Mark J. RATAIN, The University of Chicago Medicine, USA
Martine F. ROUSSEL, St. Jude Children’s Research Hospital, USA
David SIDRANSKY, The Johns Hopkins University, USA
Makoto Mark TAKETO, Kyoto University, Japan
Karen VOUSDEN, The Beatson Institute for Cancer Research, UK
Hai YAN, Duke University, USA
Pan-Chyr YANG, National Taiwan University, Taiwan
Dario CAMPANA, National University Cancer Institute, Singapore
Polly CHEN, Cancer Science Institute of Singapore
CHNG Wee Joo, Cancer Science Institute of Singapore
Steve COHEN, Institute of Molecular and Cell Biology
Peter DROGE, Nanyang Technological University
Ernesto GUCCIONE, Institute of Molecular and Cell Biology
Koji ITAHANA, Duke-NUS Graduate Medical School
Philipp H. KOEFFLER, National University Cancer Institute, Singapore
Sang Hyun LEE, Duke-NUS Graduate Medical School
LIM Soon Thye, National Cancer Centre Singapore
Daniela RHODES, Nanyang Technological University
Kanaga SABAPATHY, National Cancer Centre Singapore
Toshio SUDA, Cancer Science Institute of Singapore
TEH Bin Tean, National Cancer Centre Singapore
Qi ZENG, Institute of Molecular and Cell Biology
FCS 2012
FCS 2012
University Cultural Centre, NUS
Elizabeth H. BLACKBURN (KEYNOTE), University of California, San Francisco, USA Recipient of the 2009 Nobel Prize in Physiology or Medicine
Jules A. HOFFMANN (KEYNOTE), Institut de Biologie Moleculaire et Cellulaire, France Recipient of the 2011 Nobel Prize in Physiology or Medicine
Roger Y. TSIEN (KEYNOTE), University of California, San Diego, USA Recipient of the 2008 Nobel Prize in Chemistry
Constanze BONIFER, University of Birmingham, UK
Peter JONES, USC Norris Comprehensive Cancer Center, USA
Gustavo LEONE, The Ohio State University, USA
Hiroyuki MANO, University of Tokyo, Japan
John MATTICK, Garvan Institute of Medical Research, Australia
Martin McMAHON, UCSF Helen Diller Family Comprehensive Cancer Center, USA
Peter RATCLIFFE, Head, University of Oxford, UK
Inder VERMA, Salk Institute for Biological Studies, USA
Xiao Fan WANG, Duke University Medical Center, USA
Paul WORKMAN, The Institute of Cancer Research, UK
DAN Yock Young, National University Cancer Institute, Singapore
HONG Wanjin, Institute of Molecular and Cell Biology
Barbara KNOWLES, Institute of Medical Biology
Darren LIM, National Cancer Centre Singapore
Eugene MAKEYEV, Nanyang Technological University
ONG Choon Kiat, National Cancer Centre Singapore
ONG Sin Tiong, Duke-NUS Graduate Medical School
Lorenz POELLINGER, Cancer Science Institute of Singapore
Steve ROZEN, Duke-NUS Graduate Medical School
Prabha SAMPATH, Institute of Medical Biology
SU I-Hsin, Nanyang Technological University
Patrick TAN, Duke-NUS Graduate Medical School
Daniel G. TENEN, Cancer Science Institute of Singapore
Vinay TERGAONKAR, Institute of Molecular and Cell Biology
David M. VIRSHUP, Duke-NUS Graduate Medical School
FCS 2011
FCS 2011
Joseph SCHLESSINGER (KEYNOTE), Yale University School of Medicine, USA
Mina J. BISSELL, Lawrence Berkeley National Laboratory, USA
Lewis C. CANTLEY, Harvard Medical School, USA
Tsutomu CHIBA, Kyoto University, Japan
Alan D’ANDREA, Dana-Farber Cancer Institute, USA
David A. JONES, The University of Utah, USA
Frank McCORMICK, University of California, San Francisco, USA
Donald P. McDONNELL, Duke University Medical School, USA
Sean J. MORRISON, University of Michigan, USA
Shigekazu NAGATA, Kyoto University, Japan
Louis M. STAUDT, National Cancer Institute, USA
David A. TUVESON, Cambridge Research Institute, UK
Jane VISVADER, The Walter and Eliza Hall Institute of Medical Research, Australia
Fiona M. WATT, Cambridge Research Institute, UK
Kevin P. WHITE, The University of Chicago, USA
Jean-Pierre ABASTADO, Singapore Immunology Network
Rebecca DENT, National Cancer Centre Singapore
FU Xin-Yuan, Cancer Science Institute of Singapore
GOH Boon Cher, Cancer Science Institute of Singapore
Koji ITAHANA, Duke-NUS Graduate Medical School
Philipp KALDIS, Institute of Molecular and Cell Biology
David LANE, p53 Lab, A*STAR
LIM Chwee Teck, Mechanobiology Institute
Peter LOBIE, Cancer Science Institute of Singapore
John LUK, Cancer Science Institute of Singapore
Frank McKEON, Genome Institute of Singapore
TAN Nguan Soon, Andrew, Nanyang Technological University
TAN Soo Yong, SingHealth
Mei WANG-CASEY, Duke-NUS Graduate Medical School
YEOH Khay Guan, National University of Singapore
FCS 2010
FCS 2010
NUHS Tower Block
Stephen QUAKE (KEYNOTE), Stanford University, USA
Philip BEACHY, Stanford School of Medicine, USA
Robert BENEZRA, Memorial Sloan-Kettering Cancer Centre, USA
Michael CLARKE, Stanford University, USA
Chi Van DANG, Johns Hopkins University, USA
Napoleone FERRARA, Genentech, USA
Andrew FUTREAL, Wellcome Trust Sanger Institute, UK
William C. HAHN, Dana-Farber Cancer Institute, USA
Masanori HATAKEYAMA, University of Tokyo, Japan
Michael KAHN, University of Southern California, USA
Tak W. MAK, University of Toronto, Canada
Markus MÜSCHEN, University of California San Francisco, USA
Paul POLAKIS, Genentech, USA
Eileen WHITE, Rutgers University, USA
Nick BARKER, Institute of Medical Biology
Dmitry BULAVIN, Institute of Molecular and Cell Biology
Patrick CASEY, Duke-NUS Graduate Medical School
CHNG Wee Joo, Cancer Science Institute of Singapore
Neal COPELAND, Institute of Molecular and Cell Biology
Nancy JENKINS, Institute of Molecular and Cell Biology
LEE Soo Chin, Cancer Science Institute of Singapore
Bing LIM, Genome Institute of Singapore
RUAN Yijun, Genome Institute of Singapore
Kanaga SABAPATHY, Duke-NUS Graduate Medical School
Uttam SURANA, Institute of Molecular and Cell Biology
Patrick TAN, Duke-NUS Graduate Medical School
TEH Bin Tean, National Cancer Centre Singapore
Allen YEOH, National Cancer Centre Singapore
YU Qiang, Genome Institute of Singapore
FCS 2009
FCS 2009
Clinical Research Centre, NUS
Mariano BARBACID, Spanish National Cancer Research Center (CNIO), Spain
Tadatsugu TANIGUCHI, University of Tokyo, Japan
Irving L. WEISSMAN, Stanford University School of Medicine, USA
Stephen NIMER, Memorial Sloan-Kettering Cancer Center, USA
Anthony GREEN, University of Cambridge, UK
Edward SETO, H. Lee Moffitt Cancer Center & Research Institute, USA
Charles LEE, Harvard Medical School, USA
Anthony GREEN, University of Cambridge, UK
David LANE, p53 Lab, A*STAR
Nancy JENKINS, Institute of Molecular and Cell Biology
Bing LIM, Genome Institute of Singapore
NG Huck Hui, Genome Institute of Singapore
ONG Sin Tiong, Duke-NUS Graduate Medical School
Conference Partner
Premium Sponsors
Standard Plus Sponsor
Standard Sponsors
Media Partner
**Inclusion of the sponsors’ names and/or logos does not imply CSI Singapore’s / NUS’ / FCS’ endorsement of the sponsors’ products and/or services.
Executive Committee
Polly Leilei CHEN
Polly Leilei CHEN
Cancer Science Institute of Singapore
Dr Polly Leilei Chen got her Bachelor of Medicine in 2002 from Medical school, Jiangsu University, China, followed by 2-year specialized training in Obstetrics & Gynaecology. She completed her PhD in Cancer Genetics in Prof. Xin-Yuan Guan’s laboratory at the University of Hong Kong in 2010. After 2-year postdoctoral training in the same lab, she joined NUS as a Principal Investigator at Cancer Science Institute of Singapore and Assistant professor in the Department of Anatomy in 2014. She has recently been promoted to Associate Professor.
Dr. Chen’s research interest has centered on transcriptome alterations in human cancers and in particular on understanding how A-to-I RNA editing contributes to cancer initiation and progression. She currently places focus on the regulators of RNA editing, the crosstalk between RNA editing and other RNA processes, and the development of RNA-based therapeutics targeting cancer-driven editing events.
Sanjay DE MEL
Sanjay DE MEL
National University Cancer Institute Singapore
Dr Sanjay de Mel graduated from the School of Medicine, University of Southampton in 2005. He completed training in general medicine at the Southampton University Hospital, UK and National University Hospital in Singapore. He subsequently completed his advanced specialist training in Haematology at the National University Cancer Institute, Singapore under the National University Health System.
Marco FOIANI
Marco FOIANI
Cancer Science Institute of Singapore
A molecular biologist by training, Marco Foiani is professor at the National University of Singapore (NUS) and senior principal investigator at the Cancer Science Institute (CSI) of Singapore. Foiani obtained his Ph.D in molecular and cell biology from University of Milan in 1988. in 1989, he moved to the National Institute of Health (NICHD) in Bethesda, USA for his post-doctoral studies and remained there till 1991. In 1991, he joined as an assistant professor the University of Milan where he started his career in the field of chromatin dynamics. He became associate professor (1995) and subsequently professor (2001) at the University of Milan. He was one of the first scientists to join IFOM. The Genome integrity research lab started functioning in 2000 with the aim of studying the various pathways that safeguard genomic integrity and play a role in oncogenesis. He was he Scientific Director of IFOM (2009 to 2022). He has been a member of the editorial board of Cell (2009-2019), and is a member of the Academia Europea and EMBO. His major contributions are within the fields of chromosome dynamics and genome integrity. His work has contributed to elucidate the ATR and ATM-dependent checkpoint processes controlling the interfaces between DNA replication, recombination, transcription and DNA topology and preventing abnormal chromosome transitions. In recent years, focus of his research has geared more towards the connections between cell metabolism and genome integrity pathways and between chromosome dynamics and mechano-transduction circuits controlling cell and nuclear plasticity.
Narayanan Gopalakrishna IYER
Narayanan Gopalakrishna IYER
National Cancer Centre Singapore
Dr Iyer graduated top of his medical school class at NUS in 1998, with Honours. He subsequently went on to complete a PhD in molecular carcinogenesis at the University of Cambridge under Prof Carlos Caldas. Trained as a General surgeon at Singapore General Hospital he went on to two separate head and neck surgical fellowships at Sydney Head and Neck Cancer Institute at Royal Prince Alfred Hospital, Australia and Memorial Sloan-Kettering Cancer Centre (MSKCC), New York, USA. At the end of his fellowship at MSKCC, he was awarded the Michael Burt award for being the best fellow in the surgical division both in terms of operative skill and research output.
Currently, Dr Gopal Iyer works as a head and neck surgeon in National Cancer Centre and Singapore General Hospital. He is also Senior Consultant of the SingHealth Duke-NUS Head and Neck Centre. Dr Gopal has extensive experience in the surgical management of head and neck cancers, as well as surgery for benign diseases in the head and neck (including thyroid, salivary gland and skin lesions). He performs complex resections and reconstructions of cancers involving the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, paranasal sinuses and neck. He is involved in the robotic and endoscopic head and neck surgical program having performed a number of these procedures locally and mentored the first ever robotic thyroidectomy in Australia in Feb 2012.
Ann LEE-LIM
Ann LEE-LIM
National Cancer Centre Singapore
Dr. Ann Lee is a Principal Investigator at the National Cancer Centre Singapore, and is an Adjunct Associate Professor at both the Duke-NUS Medical School and the National University of Singapore (NUS). She majored in Pathology at the University of Melbourne where she obtained her BSc(Hons), and completed her MSc (Immunology) at NUS and DPhil(Oxon) (Molecular Pathology) at the University of Oxford. She has trained at the Peter MacCallum Cancer Centre in Melbourne and the John Radcliffe Hospital in Oxford, and is a Fellow of the Royal College of Pathologists (UK).
Dr. Lee’s research group has received funding from the National Medical Research Council (NMRC) of Singapore, Biomedical Research Council (BMRC) of Singapore and A*STAR (Industry Alignment Fund grants). Her research focuses on biomarker discovery and identifying cancer risk markers. Current research interests are to develop blood-based assays for cancer which may be utilised for the early detection of cancer.
Besides research, Dr. Lee teaches at NUS and has served as a grant reviewer for the NMRC for 12 years, and as a member of the international UICC TNM Expert Panel for breast cancer.
Joanne NGEOW
Joanne NGEOW
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
Dr Joanne Ngeow, BMedSci, MBBS, FRCP, MPH is Associate Professor (Genomic Medicine) at the Lee Kong Chian School of Medicine, Nanyang Technological University Singapore and Senior Consultant, Division of Medical Oncology at the National Cancer Centre Singapore. Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic interest in hereditary cancer syndromes and translational clinical cancer genetics. Her team is the go-to for clinical and translational cancer genetics in Singapore and the region. Dr Ngeow was awarded consecutive fellowships by the National Medical Research Council to complete formal clinical and wet bench training in Cancer Genomic Medicine at the Genomic Medicine Institute, Cleveland Clinic, Ohio. Dr Ngeow is funded by the National Medical Research Council and Ministry of Health to explore how gene-environmental interactions predisposes to cancer initiation and progression and the implementation of genomics into routine clinical care.
Sin Tiong ONG
Sin Tiong ONG
Duke-NUS Medical School, Singapore
Coming soon.
Shazib PERVAIZ
Shazib PERVAIZ
Yong Loo Lin School of Medicine, National University of Singapore
Shazib Pervaiz holds a Full Professorship in the Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore. Over the years, he has held various leadership positions at the YLL School of Medicine, such as Vice Dean (Research and Graduate Education) and is a Distinguished Visiting Fellow at the Faculty of Health Sciences, Curtin University, Perth, Australia. He is spearheading a group investigating cellular redox status and its impact on cancer cell fate decisions with an overall objective of identifying novel targets for therapeutic intervention. He has authored more than 145 research papers and book chapters and his research work is highly cited in the field, as indicated by over 12000 citations and an H-index of 52 (by Google Scholar). He has been an invited speaker at several international and regional conferences and is serving on the editorial boards of several international peer-reviewed journals. He was elected to the European Cell Death Organization (ECDO) Academy in 2013. Being a Clinician Scientist, he also has an extensive understanding of working with the healthcare sector as well as with the biotechnology and pharmaceutical industries.
Kanaga SABAPATHY
Kanaga SABAPATHY
National Cancer Centre Singapore
Dr. Kanaga Sabapathy obtained his B.Sc.(Hons) degree in Zoology from the National University of Singapore, and his Ph.D. in Molecular & Cellular Immunology from the Institute for Molecular & Cellular Biology, Singapore, in 1995. His post-doctoral work was conducted at the Institute of Molecular Pathology (Austria), studying the c-Jun-N-terminal kinase signaling pathway. He moved to the National Cancer Centre Singapore in late 1999 as the Principal Investigator of the Laboratory of Molecular Carcinogenesis, and since 2013, was the overall Head of the Division of Cellular & Molecular Research. Dr Sabapathy was a Professor and Deputy Program Director of the Cancer and Stem Cell Biology Program at Duke-NUS. Recently, he moved to become the President’s Chair Professor and Chair of the School of Biological Sciences at the Nanyang Technological University. He is a Fellow of the Royal College of Pathologists (UK), and a recipient of the National Research Foundation Investigatorship award. Dr Sabapathy’s group focuses on investigating the molecular mechanisms involved in cancer development and response to therapy. His research is aimed at both understanding the molecular nature of cancer and designing effective targeted-therapies against the disease.
Wai Leong TAM
Wai Leong TAM
Genome Institute of Singapore, A*STAR, Singapore, Cancer Science Institute of Singapore
Wai Leong TAM performed his PhD research on stem cell biology at the Genome Institute of Singapore (GIS, A*STAR). He undertook his postdoctoral training at the Whitehead Institute/MIT, where he concentrated on understanding breast cancer stem cell biology and cancer metastasis. He then joined the GIS and the Cancer Science Institute of Singapore as a faculty member. His lab focuses on uncovering emerging paradigms of cancer stem cells, specifically in the areas of cancer metabolism, cell state transitions, and tumor microenvironment. Current efforts are focused on identifying and validating preclinical targets that can lead into drug development, as well as translating fundamental discoveries into paradigms that can help change and advance clinical practice.
Vinay TERGAONKAR
Vinay TERGAONKAR
Institute for Molecular and Cell Biology, A*STAR, Singapore
Vinay Tergaonkar obtained his Ph.D. (2001) through an international cancer society (UICC) fellowship for collaborative research at Tufts University, Boston, USA. He has been a fellow (2001-2004) and a special fellow (2004-present) of the Leukemia and Lymphoma Society of America and conducted his postdoctoral studies at the Salk Institute for Biological Studies, La Jolla, California. He joined the
Institute of Molecular and Cell Biology (IMCB), Singapore, in late 2005 as Principal Investigator and became a Senior Principal Investigator in 2010 and Research Director in 2015. He is also a Professor at School of Medicine at National University of Singapore. He serves on Editorial Boards of 1) Science Advances (AAAS), 2) Molecular and Cellular Biology (American Society for Molecular Biology), 3) Biochemical Journal (Portland Press) 4) Critical Reviews in Oncology/Hematology (Elsevier Press), 5) BMC Research Notes (Biomed Central) and 6) Telomeres and Telomerase. Work from his lab has received international recognition including the British council development award (2014) and the Premiers’ fellowship from Government of South Australia (2015).
Ashok VENKITARAMAN
Ashok VENKITARAMAN (Chair)
Cancer Science Institute of Singapore
Professor Ashok Venkitaraman is the Director of the Cancer Science Institute of Singapore, and a Distinguished Professor of Medicine at NUS Yong Loo Lin School of Medicine. He was from 1998-2020 the Ursula Zoellner Professor of Cancer Research at the University of Cambridge, and former Director of the MRC Cancer Unit. He is recognized for elucidating how a class of human genes, exemplified by the breast cancer gene BRCA2, preserves genome stability to suppress carcinogenesis. He has developed new technologies to accelerate drug discovery, and is a serial biotech entrepreneur, most recently as a founder of PhoreMost Ltd. Prof. Venkitaraman has been elected a Fellow of the Academy of Medical Sciences, London, and a member of EMBO, Heidelberg.
David VIRSHUP
David VIRSHUP
Duke-NUS Medical School, Singapore
David Virshup, M.D., is Director of the Programme in Cancer and Stem Cell Biology (CSCB) and Professor at Duke-NUS Medical School and is jointly appointed as Professor of Pediatrics at Duke University in North Carolina.
Dr. Virshup received his B.A. magna cum laude from Beloit College, majoring in chemistry. He received his M.D. from Johns Hopkins University in Baltimore, followed by clinical residency in Pediatrics and a fellowship in Pediatric Hematology/Oncology. He credits his research training and mentoring to William Zinkham, Vann Bennett, and Tom Kelly in the departments of Pediatrics, Cell Biology and Anatomy, and Molecular Biology and Genetics, all at Hopkins. Dr. Virshup established his first independent laboratory at the University of Utah in Salt Lake City, where over the course of 17 years he rose to Professor of Pediatrics and Oncological Sciences with an endowed chair as an investigator at the Huntsman Cancer Institute. He moved to Duke-NUS in Singapore in 2007 to help establish CSCB.
He has been elected to several honorific societies including the American Society for Clinical Investigation (ASCI), the American Association for the Advancement of Science (AAAS) and the Association of American Physicians (AAP). He is board certified in both Pediatrics and Pediatric Hematology/Oncology in the USA.
His research has focused on signal transduction, with an emphasis on both Wnt signaling and circadian rhythms. Early work examined the roles of Protein Phosphatase 2A and Casein Kinase 1 play in these processes. In Singapore, studies of phosphorylation of the PERIOD protein lead to the elucidation of the phosphoswitch model controlling circadian clock speed. In addition, his laboratory collaborated to develop a small molecule inhibitor of Wnt secretion, ETC-159, a drug now in human clinical trials.
Walter HUNZIKER
Walter HUNZIKER
Institute of Molecular & Cell Biology, A*STAR
Walter Hunziker obtained his PhD from the Swiss Federal Institute of Technology (Zurich) in Natural Sciences in 1986 for the cloning of the cDNA of the small intestinal brush border enzyme sucrase-isomaltase. He did postdoctoral work at Yale University where he identified signals that target membrane proteins to the basolateral surface of epithelial cells. In 1992 he moved to the Biochemistry Institute of the University of Lausanne as a group leader, continuing to study membrane traffic in epithelial cells and was appointed Assistant Professor in 1996. He joined IMCB in January 2000 as an Associate Professor and is Deputy Director of IMCB.
Cinnie SOEKOJO
Cinnie SOEKOJO
National University Cancer Institute Singapore
Dr Cinnie Soekojo is a consultant at the National University Cancer Institute, Singapore. She completed her internal medicine residency at the National University Hospital, Singapore, and obtained her post-graduate qualification from the Royal Colleges of Physicians, United Kingdom. She continued with her advanced specialty training in hematology at the National University Cancer Institute, Singapore, and obtained her Fellowship of the Royal College of Pathologists, United Kingdom. To further her training in multiple myeloma and cellular therapy, she completed a one-year advanced hematology fellowship in multiple myeloma, amyloidosis, and dysproteinemia at Mayo Clinic in Rochester, Minnesota, United States.
Her research interest is in the study of genomics, immune microenvironment, and the interaction between tumor and immune cells with single-cell sequencing and spatial omics. She did her postdoctoral research fellowship at the Dana-Farber Cancer Institute, Broad Institute of MIT and Harvard, and Harvard Medical School in Boston, Massachusetts, United States. She has published in several peer-reviewed journals and has also presented at regional and international meetings. She has received several awards and holds several grants for her research and is currently involved in clinical trials and translational research in her field of interest.
Robert WALSH
Robert WALSH
National University Cancer Institute Singapore
Dr Robert Walsh obtained his undergraduate medical degree from the University of Cambridge, England before undertaking Foundation training at the University Hospitals of Leicester NHS Trust. He has worked in the Singapore health system since 2013 and obtained his postgraduate qualifications from the Royal College of Physicians (UK) in 2015. Dr Walsh subsequently completed postgraduate residency training in Internal Medicine and Medical Oncology at the National University Health System, Singapore. His areas of clinical and research interests include gastrointestinal cancer, genitourinary cancer, and precision oncology.
Xiaomeng WANG
Xiaomeng WANG
Duke-NUS Medical School, Singapore
Dr. Xiaomeng Wang is an Associate Professor at the Centre for Vison Research, Duke-NUS Medical School. Prior to this appointment, Dr. Wang worked as an Associate Professor at the Lee Kong Chian School of Medicine, Nanyang Technological University Singapore. Dr. Wang obtained her BSc. in Biology at Beijing Normal University, China and her PhD in Genetics at Newcastle University, UK. Thereafter, she undertook post-doctoral training at Manchester University and University College London, UK.
Gallery
Contact
Steven JONES
The University of British Columbia, CA
Dr Jones gained his PhD at the Sanger Institute, Cambridge, where he was involved in the C. elegans genome project. Currently, he is Head of Bioinformatics and Co-Director of the Genome Sciences Centre at BC Cancer in Vancouver. Dr Jones has played a role in numerous other genome projects, including that of the human, mouse, rat, bovine, fruitfly and the SARS coronavirus.
Dr Jones’s research focus is the computational analysis of DNA sequence and the analysis of genomic and transcriptomic data. He has applied next-generation DNA sequencing technology to determine the mutations and rearrangements driving many tumour types. A key goal is to develop bioinformatic approaches to predict the most efficacious therapies from the genetic analysis of patient tumour samples to help guide clinical decision making.
Amongst Dr. Jones many and varied honours and awards he is a Fellow of the Royal Society of Canada as well as the Canadian Academy of Health Sciences. In 2014 and again in 2016, he was named by Thomson Reuters as one of the world's most influential researchers being in the top 1% of cited scientists. In 2018, 2019, and 2020. Dr. Jones is Canada Research Chair in Computational Genomics at the University of British Columbia.
He has been invited to give over 167 presentations, nationally and internationally, is an author on over 535 peer-reviewed publications (Google Scholar h-index 152) and is Principal Investigator and co-applicant on grants that have totaled over $700 million to date.